SAN DIEGO, Nov. 30, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time. The goal of this 12-month study of ZX002 is to evaluate overall safety in at least 300 patients for six months and at least 100 patients for one year. With successful conclusion of the enrollment of 450 patients for this study, the top-line long-term safety results are anticipated to be available in the second half of 2011.
